Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).

Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y.

Clin Cancer Res. 2019 Sep 15;25(18):5485-5492. doi: 10.1158/1078-0432.CCR-19-0103. Epub 2019 Jun 4.

PMID:
31164373
2.

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).

Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K; HER2-CS Network.

Chest. 2019 Aug;156(2):357-366. doi: 10.1016/j.chest.2019.01.011. Epub 2019 May 6.

PMID:
31072612
3.

Physician requests by patients with malignant pleural mesothelioma in Japan.

Nagamatsu Y, Oze I, Aoe K, Hotta K, Kato K, Nakagawa J, Hara K, Kishimoto T, Fujimoto N.

BMC Cancer. 2019 Apr 25;19(1):383. doi: 10.1186/s12885-019-5591-7.

4.

Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.

Sato H, Soh J, Aoe K, Fujimoto N, Tanaka S, Namba K, Torigoe H, Shien K, Yamamoto H, Tomida S, Tao H, Okabe K, Kishimoto T, Toyooka S.

Int J Oncol. 2019 Jun;54(6):2139-2148. doi: 10.3892/ijo.2019.4768. Epub 2019 Apr 1.

PMID:
30942424
5.

Pleural effusion related to IgG4.

Murata Y, Aoe K, Mimura Y.

Curr Opin Pulm Med. 2019 Jul;25(4):384-390. doi: 10.1097/MCP.0000000000000581.

6.

Benefits of a Nationwide Palliative Care Education Program on Lung Cancer Physicians.

Inoue A, Yamaguchi T, Tanaka K, Sakashita A, Aoe K, Seki N, Hagiwara K.

Intern Med. 2019 May 15;58(10):1399-1403. doi: 10.2169/internalmedicine.0872-18. Epub 2019 Feb 1.

7.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.

Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.

PMID:
30268482
8.

A Case of Localized Pleural Amyloidosis: Multimodality Imaging Features.

Kunihiro Y, Onoda H, Aoe K, Furukawa M, Okabe K, Murakami T, Hoshii Y, Tanaka N, Matsumoto T.

J Thorac Imaging. 2018 Nov;33(6):W54-W56. doi: 10.1097/RTI.0000000000000354. No abstract available.

PMID:
30142135
9.

A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.

Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K.

Clin Lung Cancer. 2018 Sep;19(5):e705-e707. doi: 10.1016/j.cllc.2018.05.001. Epub 2018 May 9.

10.

Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study.

Shintani Y, Hasegawa S, Takuwa T, Aoe K, Kato K, Fujimoto N, Hida Y, Morise M, Moriya Y, Morohoshi T, Okumura M, Yoshino I.

J Thorac Dis. 2018 Mar;10(3):1968-1971. doi: 10.21037/jtd.2018.03.53.

11.

Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.

Nagamatsu Y, Oze I, Aoe K, Hotta K, Kato K, Nakagawa J, Hara K, Kishimoto T, Fujimoto N.

BMC Cancer. 2018 Mar 27;18(1):350. doi: 10.1186/s12885-018-4293-x.

12.

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.

Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.

Oncogenesis. 2018 Jan 24;7(1):11. doi: 10.1038/s41389-017-0017-3.

13.

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.

Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K.

J Thorac Oncol. 2018 Feb;13(2):273-279. doi: 10.1016/j.jtho.2017.10.032. Epub 2017 Dec 5.

14.

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.

Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Kuyama S, Kudo K, Bessho A, Fukamatsu N, Fujimoto N, Aoe K, Shibayama T, Sugimoto K, Takigawa N, Hotta K, Kiura K.

Lung Cancer. 2018 Jan;115:103-108. doi: 10.1016/j.lungcan.2017.11.025. Epub 2017 Nov 28.

PMID:
29290249
15.

Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).

Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K.

Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4.

16.

Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion.

Murata Y, Aoe K, Mimura-Kimura Y, Murakami T, Oishi K, Matsumoto T, Ueoka H, Matsunaga K, Yano M, Mimura Y.

Clin Exp Immunol. 2017 Oct;190(1):133-142. doi: 10.1111/cei.12999. Epub 2017 Jul 17.

17.

Erratum to "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer" [Lung Cancer 76 (1) (2012) 32-38].

Tanaka N, Toyooka S, Soh J, Kubo T, Yamamoto H, Maki Y, Muraoka T, Shien K, Furukawa M, Ueno T, Asano H, Tsukuda K, Aoe K, Miyoshi S.

Lung Cancer. 2017 Jun;108:254-255. doi: 10.1016/j.lungcan.2016.04.016. Epub 2017 Apr 27. No abstract available.

PMID:
28457607
18.

Survival from an Acute Exacerbation of Idiopathic Pulmonary Fibrosis with or without Direct Hemoperfusion with a Polymyxin B-immobilized Fiber Column: A Retrospective Analysis.

Oishi K, Aoe K, Mimura Y, Murata Y, Sakamoto K, Koutoku W, Matsumoto T, Ueoka H, Yano M.

Intern Med. 2016;55(24):3551-3559. Epub 2016 Dec 15.

19.

Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion.

Kato K, Gemba K, Fujimoto N, Aoe K, Takeshima Y, Inai K, Kishimoto T.

Eur J Radiol. 2016 Sep;85(9):1594-600. doi: 10.1016/j.ejrad.2016.06.013. Epub 2016 Jun 21.

PMID:
27501894
20.

Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.

Ohashi K, Hotta K, Hirata T, Aoe K, Kozuki T, Ninomiya K, Kayatani H, Yanai H, Toyooka S, Hinotsu S, Takata M, Kiura K.

Clin Lung Cancer. 2017 Jan;18(1):92-95. doi: 10.1016/j.cllc.2016.06.014. Epub 2016 Jul 9.

PMID:
27497829
21.

Erratum to: Fatal pleural mesothelioma in Japan (2003-2008): evaluation of computed tomography findings.

Kato K, Gemba K, Fujimoto N, Aoe K, Takeshima Y, Inai K, Kishimoto T.

Jpn J Radiol. 2016 Jun;34(6):439. No abstract available.

PMID:
27055848
22.

Fatal pleural mesothelioma in Japan (2003-2008): evaluation of computed tomography findings.

Kato K, Gemba K, Fujimoto N, Aoe K, Takeshima Y, Inai K, Kishimoto T.

Jpn J Radiol. 2016 Jun;34(6):432-8. doi: 10.1007/s11604-016-0539-1. Epub 2016 Mar 25. Erratum in: Jpn J Radiol. 2016 Jun;34(6):439.

PMID:
27015837
23.

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.

Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, Komura N, Eguchi K.

Support Care Cancer. 2016 Aug;24(8):3495-505. doi: 10.1007/s00520-016-3144-z. Epub 2016 Mar 23.

24.

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.

Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K.

Support Care Cancer. 2016 Aug;24(8):3473-80. doi: 10.1007/s00520-016-3156-8. Epub 2016 Mar 22.

25.

Computed Tomographic Features of Malignant Peritoneal Mesothelioma.

Kato K, Gemba K, Fujimoto N, Aoe K, Takeshima Y, Inai K, Kishimoto T.

Anticancer Res. 2016 Mar;36(3):1067-72.

PMID:
26976999
26.

Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma.

Suzawa K, Yamamoto H, Murakami T, Katayama H, Furukawa M, Shien K, Hashida S, Okabe K, Aoe K, Soh J, Asano H, Tsukuda K, Mimura Y, Toyooka S, Miyoshi S.

Oncol Lett. 2016 Jan;11(1):705-712. Epub 2015 Nov 23.

27.

DNA copy number gains in malignant pleural mesothelioma.

Furukawa M, Toyooka S, Hayashi T, Yamamoto H, Fujimoto N, Soh J, Hashida S, Shien K, Asano H, Aoe K, Okabe K, Pass HI, Tsukuda K, Kishimoto T, Miyoshi S.

Oncol Lett. 2015 Nov;10(5):3274-3278. Epub 2015 Aug 27.

28.

Clinical Investigation of Benign Asbestos Pleural Effusion.

Fujimoto N, Gemba K, Aoe K, Kato K, Yokoyama T, Usami I, Onishi K, Mizuhashi K, Yusa T, Kishimoto T.

Pulm Med. 2015;2015:416179. doi: 10.1155/2015/416179. Epub 2015 Nov 24.

29.

Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.

Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, Otsuka K, Morita S, Kimura S, Negoro S; Hanshin-Saga Collaborative Cancer Study Group.

Cancer Sci. 2016 Feb;107(2):162-7. doi: 10.1111/cas.12847. Epub 2016 Jan 19.

30.

Vigorous inflammatory responses in noninfectious pulmonary complication induced by donor lymphocyte infusion.

Nishie M, Fujii N, Mimura Y, Asano T, Mimura-Kimura Y, Aoe K, Aoe M, Nakashima H, Fujiwara H, Nishimori H, Matsuoka K, Kondo E, Maeda Y, Tanimoto M.

Transfusion. 2016 Jan;56(1):231-6. doi: 10.1111/trf.13283. Epub 2015 Oct 9.

PMID:
26449992
31.

Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, Aoe K, Ueoka H, Hosokawa S, Bessho A, Hisamoto-Sato A, Kubo T, Oze I, Takigawa N, Tanimoto M, Kiura K.

J Thorac Oncol. 2015 Mar;10(3):486-91. doi: 10.1097/JTO.0000000000000434.

32.

A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.

Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, Oze I, Kishino D, Aoe K, Ueoka H, Kuyama S, Harita S, Okada T, Hosokawa S, Inoue K, Gemba K, Shibayama T, Tabata M, Takemoto M, Kanazawa S, Tanimoto M, Kiura K.

Lung Cancer. 2015 Feb;87(2):141-7. doi: 10.1016/j.lungcan.2014.11.001. Epub 2014 Nov 8.

PMID:
25534129
33.

Clinical significance of soluble CD26 in malignant pleural mesothelioma.

Fujimoto N, Ohnuma K, Aoe K, Hosono O, Yamada T, Kishimoto T, Morimoto C.

PLoS One. 2014 Dec 19;9(12):e115647. doi: 10.1371/journal.pone.0115647. eCollection 2014.

34.

A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.

Aoe K, Takigawa N, Hotta K, Maeda T, Kishino D, Nogami N, Tabata M, Harita S, Okada T, Kubo T, Hosokawa S, Fujiwara K, Gemba K, Yasugi M, Kozuki T, Kato Y, Katsui K, Kanazawa S, Ueoka H, Tanimoto M, Kiura K.

Eur J Cancer. 2014 Nov;50(16):2783-90. doi: 10.1016/j.ejca.2014.07.024. Epub 2014 Aug 26.

PMID:
25172295
35.

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma.

Yamamoto J, Ohnuma K, Hatano R, Okamoto T, Komiya E, Yamazaki H, Iwata S, Dang NH, Aoe K, Kishimoto T, Yamada T, Morimoto C.

Br J Cancer. 2014 Apr 29;110(9):2232-45. doi: 10.1038/bjc.2014.151. Epub 2014 Apr 17.

36.

The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.

Muraoka T, Soh J, Toyooka S, Aoe K, Fujimoto N, Hashida S, Maki Y, Tanaka N, Shien K, Furukawa M, Yamamoto H, Asano H, Tsukuda K, Kishimoto T, Otsuki T, Miyoshi S.

Lung Cancer. 2013 Dec;82(3):485-90. doi: 10.1016/j.lungcan.2013.09.017. Epub 2013 Oct 10.

37.

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.

Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T.

Invest New Drugs. 2013 Oct;31(5):1275-82. doi: 10.1007/s10637-013-9941-z. Epub 2013 Mar 10. Erratum in: Invest New Drugs. 2013 Oct;31(5):1395-6.

PMID:
23475281
38.

CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.

Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T, Kishimoto T, Morimoto C, Inai K.

Oncol Rep. 2013 Jan;29(1):21-8. doi: 10.3892/or.2012.2116. Epub 2012 Oct 31.

39.

Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Oishi K, Mimura-Kimura Y, Miyasho T, Aoe K, Ogata Y, Katayama H, Murata Y, Ueoka H, Matsumoto T, Mimura Y.

Cytokine. 2013 Jan;61(1):84-9. doi: 10.1016/j.cyto.2012.08.032. Epub 2012 Sep 26.

PMID:
23021430
40.

Treatment and survival analyses of malignant mesothelioma in Japan.

Gemba K, Fujimoto N, Aoe K, Kato K, Takeshima Y, Inai K, Kishimoto T.

Acta Oncol. 2013 May;52(4):803-8. doi: 10.3109/0284186X.2012.709948. Epub 2012 Aug 29.

PMID:
22928694
41.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W.

Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):E2127-33. doi: 10.1073/pnas.1203530109. Epub 2012 Jul 6.

42.

CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.

Aoe K, Amatya VJ, Fujimoto N, Ohnuma K, Hosono O, Hiraki A, Fujii M, Yamada T, Dang NH, Takeshima Y, Inai K, Kishimoto T, Morimoto C.

Clin Cancer Res. 2012 Mar 1;18(5):1447-56. doi: 10.1158/1078-0432.CCR-11-1990. Epub 2012 Jan 18.

43.

Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.

Fujii M, Fujimoto N, Hiraki A, Gemba K, Aoe K, Umemura S, Katayama H, Takigawa N, Kiura K, Tanimoto M, Kishimoto T.

Cancer Sci. 2012 Mar;103(3):510-4. doi: 10.1111/j.1349-7006.2011.02180.x. Epub 2012 Jan 13.

44.

National survey of malignant mesothelioma and asbestos exposure in Japan.

Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K, Kishimoto T.

Cancer Sci. 2012 Mar;103(3):483-90. doi: 10.1111/j.1349-7006.2011.02165.x. Epub 2012 Jan 9.

45.

Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer.

Tanaka N, Toyooka S, Soh J, Kubo T, Yamamoto H, Maki Y, Muraoka T, Shien K, Furukawa M, Ueno T, Asano H, Tsukuda K, Aoe K, Miyoshi S.

Lung Cancer. 2012 Apr;76(1):32-8. doi: 10.1016/j.lungcan.2011.10.002. Epub 2011 Nov 1. Erratum in: Lung Cancer. 2017 Jun;108:254-255.

46.

Is adenosine deaminase in pleural fluid a useful marker for differentiating tuberculosis from lung cancer or mesothelioma in Japan, a country with intermediate incidence of tuberculosis?

Ogata Y, Aoe K, Hiraki A, Murakami K, Kishino D, Chikamori K, Maeda T, Ueoka H, Kiura K, Tanimoto M.

Acta Med Okayama. 2011 Aug;65(4):259-63.

47.

Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.

Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H.

Lung Cancer. 2012 Jan;75(1):95-101. doi: 10.1016/j.lungcan.2011.06.002. Epub 2011 Jun 29.

PMID:
21719142
48.

Relapse of neuromyelitis optica spectrum disorder associated with intravenous lidocaine.

Uzawa A, Mori M, Masuda S, Aoe K, Kuwabara S.

Case Rep Med. 2011;2011:405837. doi: 10.1155/2011/405837. Epub 2011 May 11.

49.

Incidence of interstitial lung disease in patients with mesothelioma in the west part of Japan.

Nojiri S, Gemba K, Aoe K, Kato K, Yamaguchi T, Sato T, Kubota K, Kishimoto T.

Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):643-52. doi: 10.1002/pds.2123.

PMID:
21425207
50.

Identification of cancer stem cell markers in human malignant mesothelioma cells.

Ghani FI, Yamazaki H, Iwata S, Okamoto T, Aoe K, Okabe K, Mimura Y, Fujimoto N, Kishimoto T, Yamada T, Xu CW, Morimoto C.

Biochem Biophys Res Commun. 2011 Jan 14;404(2):735-42. doi: 10.1016/j.bbrc.2010.12.054. Epub 2010 Dec 14.

PMID:
21163253

Supplemental Content

Support Center